Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985882%3A_____%2F25%3A00638217" target="_blank" >RIV/67985882:_____/25:00638217 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10500554 RIV/60461373:22340/25:43932263 RIV/00064165:_____/25:10500554

Výsledek na webu

<a href="https://doi.org/10.1186/s12967-025-06885-6" target="_blank" >https://doi.org/10.1186/s12967-025-06885-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12967-025-06885-6" target="_blank" >10.1186/s12967-025-06885-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis

Popis výsledku v původním jazyce

Background: Vibrational and chiroptical spectroscopy of blood plasma is an advanced experimental diagnostic approach that allows the identification of disease-specific molecular patterns. This study aimed to test its potential to distinguish between different stages of metabolic dysfunction-associated steatotic liver disease (MASLD) including liver fibrosis. Methods: We analyzed blood plasma samples from 29 patients with metabolic dysfunction-associated steatohepatitis (MASH) and 24 MASLD patients with simple steatosis using Fourier-transform infrared (FTIR) spectroscopy, Raman spectroscopy and electronic circular dichroism (ECD) spectroscopy to distinguish: (i) MASH, (ii) MASH with moderate to advanced fibrosis, and (iii) overall fibrosis. Results: FTIR spectroscopy distinguished MASH from simple steatosis with a sensitivity of 73% and a specificity of 92%, with an area under the receiver operating characteristic curve (AUROC) of 0.92, p < 0.001. In addition, FTIR spectroscopy identified MASH with moderate to advanced fibrosis (F2–3) from MASH/steatosis with no to mild fibrosis (F0–1) with a sensitivity of 87% and specificity of 78% (AUROC 0.91, p < 0.001). Furthermore, regardless of the MASH/steatosis diagnosis, fibrosis (F1–3) was distinguished from F0 by the combination of data from the three spectroscopic methods with a sensitivity of 79% and a specificity of 88% (AUROC 0.91, p < 0.001). Both FTIR and Raman spectroscopy alone discriminated all target groups with an AUROC > 0.82. Conclusions: This pilot study revealed the potential of blood plasma spectroscopy to identify and differentiate patients with various stages of MASLD

Název v anglickém jazyce

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis

Popis výsledku anglicky

Background: Vibrational and chiroptical spectroscopy of blood plasma is an advanced experimental diagnostic approach that allows the identification of disease-specific molecular patterns. This study aimed to test its potential to distinguish between different stages of metabolic dysfunction-associated steatotic liver disease (MASLD) including liver fibrosis. Methods: We analyzed blood plasma samples from 29 patients with metabolic dysfunction-associated steatohepatitis (MASH) and 24 MASLD patients with simple steatosis using Fourier-transform infrared (FTIR) spectroscopy, Raman spectroscopy and electronic circular dichroism (ECD) spectroscopy to distinguish: (i) MASH, (ii) MASH with moderate to advanced fibrosis, and (iii) overall fibrosis. Results: FTIR spectroscopy distinguished MASH from simple steatosis with a sensitivity of 73% and a specificity of 92%, with an area under the receiver operating characteristic curve (AUROC) of 0.92, p < 0.001. In addition, FTIR spectroscopy identified MASH with moderate to advanced fibrosis (F2–3) from MASH/steatosis with no to mild fibrosis (F0–1) with a sensitivity of 87% and specificity of 78% (AUROC 0.91, p < 0.001). Furthermore, regardless of the MASH/steatosis diagnosis, fibrosis (F1–3) was distinguished from F0 by the combination of data from the three spectroscopic methods with a sensitivity of 79% and a specificity of 88% (AUROC 0.91, p < 0.001). Both FTIR and Raman spectroscopy alone discriminated all target groups with an AUROC > 0.82. Conclusions: This pilot study revealed the potential of blood plasma spectroscopy to identify and differentiate patients with various stages of MASLD

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10306 - Optics (including laser optics and quantum optics)

Projekt

<a href="/cs/project/NU23-01-00288" target="_blank" >NU23-01-00288: Komplexní změny životního stylu v léčbě nealkoholové tukové choroby jater</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Translational Medicine

ISSN

1479-5876

e-ISSN

1479-5876

Svazek periodika

23

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

868

Kód UT WoS článku

001546947200008

EID výsledku v databázi Scopus

2-s2.0-105012898836